Empagliflozin Gets Priority Review for Heart Failure Independent of LVEF
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
Diagnosis & Disease Information
Empagliflozin Benefits Patients With Heart Failure and Preserved Ejection Fraction
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
Empagliflozin Gets Breakthrough Tx Status for Heart Failure With Preserved Ejection Fraction
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
Empagliflozin Cuts Risk of Hospitalization, Death in HFpEF Patients
The phase 3 EMPEROR-Preserved trial included 5988 adult patients with heart failure with preserved ejection fraction, with and without diabetes.
Novel Oral Anticoagulant Fast Tracked for Patients With ESRD and Atrial Fibrillation
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Amplatzer Amulet Approved to Reduce Thromboembolic Risk in Atrial Fibrillation
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.
FDA Panel Votes on Omecamtiv Mecarbil for Heart Failure With Reduced Ejection Fraction
Omecamtiv mecarbil is a selective small molecule cardiac myosin activator.
New-Onset SVT Following Colonoscopy Bowel Prep Explored in Case Series
A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
Etripamil Nasal Spray Looks Promising for Self-Administered PSVT Treatment
Etripamil is a self-administered nasal spray designed to be a rapid-response therapy for episodic cardiovascular conditions.
Sotagliflozin Under Review for Heart Failure Treatment
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
- Loading...
Loading...
Next post in Cardiology
Loading... 
Loading...